Pacific Biosciences of California (PACB) 8-K Second Quarter Financial Results

Exhibit 99.1

Pacific Biosciences of California, Inc. Announces

Second Quarter Financial Results

Menlo Park, Calif.– August 4, 2011 – Pacific Biosciences of California, Inc. (Nasdaq: PACB) today announced financial results for the second quarter ended June 30, 2011.

Second Quarter 2011 Financial Results:

During the second quarter of 2011, the Company began recognizing revenue from the initial commercial deliveries of its third generation sequencing platform, the PacBio RS. Revenue for the second quarter of 2011 totaled $10.6 million, reflecting the delivery of 16 commercial PacBio RS instruments to customers, initial revenue from commercial shipments of the Company’s SMRT cell and reagent consumables, as well as revenue derived from instrument service contracts. Net loss decreased to $22.5 million as compared to the $34.8 million loss recognized for the first quarter of 2011.

“The second quarter of 2011 marks a significant milestone as PacBio has now delivered the first third generation sequencing platform to the market,” noted Hugh Martin, the Company’s Chief Executive Officer. “Researchers in North America and Europe are now armed with a technology that will enable insights into genomic research not previously possible.”

Gross profit for the second quarter totaled $7.9 million, resulting in a gross margin of 74%. Gross margin for the quarter was substantially higher than we expect to achieve in the future due to the fact that significant costs associated with the instruments sold during the second quarter were expensed during prior periods. During development, costs relating to instrument components and manufacturing costs were expensed until commercial production started.

Research and development expense during the second quarter of 2011 totaled $19.5 million representing a 19% decrease compared to $24.1 million for the first quarter. The reported expense includes non-cash stock-based compensation totaling $1.5 million and $1.4 million for the second and first quarters of 2011, respectively.

Selling, general, and administrative expense during the second quarter of 2011 of $11.0 million remained consistent with the $11.1 million for the first quarter. The reported expense includes non-cash stock-based compensation totaling $1.3 million and $1.7 million for the second and first quarters of 2011, respectively.

Cash and investments at June 30, 2011 totaled $216.6 million compared to $248.5 million at March 31, 2011.

Second Quarter 2011 Highlights

• Commercial shipments of the PacBio RS commenced in April resulting in successful customer installation and upgrades of beta instruments at customer sites.

• We completed ade novo sequencing of the E.coli strain responsible for the recent outbreak in Germany and sequenced 11 related bacterial strains using an early version of chemistry and software in development for the next major product upgrade, planned for the fourth quarter.

Quarterly Conference Call Information

Management will host a quarterly conference call to discuss its Second Quarter 2011 results today at 4:30pm Eastern / 1:30pm Pacific. Investors may listen to the call by dialing 877-415-3182, or if outside the U.S., by dialing +1-857-244-7325, and entering passcode 63187118. The call will be webcast live and will be available for replay at Pacific Biosciences’ website athttp://investor.pacificbiosciences.com/.

Forward-Looking Statements

This press release contains forward-looking statements relating to the Company’s operations and operating results, including statements relating to the Company’s plans for product upgrades. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company’s control and that could materially affect actual results. Factors that could materially affect actual results can be found in Pacific Biosciences of California’s recently filed Quarterly Report on Form 10-Q, including those listed under the caption “Risk Factors.” Pacific Biosciences of California expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Trevin Rard

650.521.8450

ir@pacificbiosciences.com

Pacific Biosciences of California, Inc.

Unaudited Consolidated Statement of Operations

(amounts in thousands, except share and per share amounts)

	Quarters Ended
	June 30, 2011			March 31, 2011			June 30, 2010
Revenue:
Product revenue	$	10,148		$	—		$	—
Service and other revenue		192			—			—
Grant revenue		290			270			629
Total revenue		10,630			270			629
Cost of revenue:
Cost of product revenue		2,537			—			—
Cost of service and other revenue		194			—			—
Total cost of revenue		2,731			—			—
Gross profit		7,899			270			629
Operating expense:
Research and development		19,546			24,118			27,082
Sales, general and administrative		11,016			11,119			6,222
Total operating expense		30,562			35,237			33,304
Operating loss		(22,663	)		(34,967	)		(32,675	)
Other income (expense), net		188			158			(39	)
Net loss	$	(22,475	)	$	(34,809	)	$	(32,714	)
Basic and diluted net loss per share	$	(0.42	)	$	(0.66	)	$	(51.20	)
Shares used in computing basic and diluted net loss per share		53,413,565			52,756,116			639,007

Pacific Biosciences of California, Inc.

Unaudited Consolidated Statement of Operations

(amounts in thousands, except per share amounts)

	Year to Date
	June 30, 2011			June 30, 2010
Revenue:
Product revenue	$	10,148		$	—
Service and other revenue		192			—
Grant revenue		560			1,174
Total revenue		10,900			1,174
Cost of revenue:
Cost of product revenue		2,537			—
Cost of service and other revenue		194			—
Total cost of revenue		2,731			—
Gross profit		8,169			1,174
Operating expense:
Research and development		43,664			52,406
Sales, general and administrative		22,135			11,717
Total operating expense		65,799			64,123
Operating loss		(57,630	)		(62,949	)
Other income (expense), net		346			(90	)
Net loss	$	(57,284	)	$	(63,039	)
Basic and diluted net loss per share	$	(1.08	)	$	(99.58	)
Shares used in computing basic and diluted net loss per share		53,056,745			633,019

Pacific Biosciences of California, Inc.

Consolidated Balance Sheets

(amounts in thousands, except per share amounts)

	June 30, 2011		March 31, 2011		December 31, 2010 (1)
	(unaudited)		(unaudited)
Assets
Cash and investments	$	216,588	$	248,548	$	283,674
Accounts receivable		5,437		59		341
Inventory		19,552		13,539		6,864
Prepaid and other current assets		3,151		2,124		2,235
Total current assets		244,728		264,270		293,114
Property and equipment		16,180		13,932		12,311
Other assets		312		356		322
Total Assets	$	261,220	$	278,558	$	305,747
Liabilities and Stockholders’ Equity
Accounts payable	$	9,032	$	9,432	$	9,515
Deferred revenue		2,381		4,350		3,221
Accrued and other current liabilities		10,050		10,350		8,104
Total current liabilities		21,463		24,132		20,840
Facility financing and deferred rent		6,431		5,755		5,041
Stockholders’ equity		233,326		248,671		279,866
Total Liabilities and Stockholders’ Equity	$	261,220	$	278,558	$	305,747

Note 1: The condensed consolidated balance sheet at December 31, 2010 has been derived from the audited consolidated financial statements at that date included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010.